Form 4: Bicara Therapeutics COO Sells Shares Under 10b5-1 Plan

Bicara Therapeutics' President and COO, Ryan Cohlhepp, sold 3,828 shares of common stock for approximately $18.10 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), reported a transaction involving the company's common stock.
• On January 22, 2026, Cohlhepp sold 3,828 shares of Bicara Therapeutics common stock.
• The shares were sold at a weighted average price of $18.1024 per share, with individual transactions ranging from $18.00 to $18.19.
• This sale was executed under a Rule 10b5-1 trading plan that was adopted on February 12, 2025.
• Following this transaction, Cohlhepp directly beneficially owns 210,164 shares of Bicara Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a key executive, while a reduction in insider ownership, was conducted under a pre-established 10b5-1 trading plan, which typically mitigates the negative signal often associated with insider sales as it suggests the transaction was not based on new, material non-public information.

Positives

• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025, indicating a pre-scheduled sale rather than a discretionary one based on new material non-public information.

Negatives

• An insider, the President and COO, sold 3,828 shares of company common stock, reducing their direct beneficial ownership.

Related Party Transactions

• Sale of 3,828 shares of common stock by Ryan Cohlhepp, President, COO, and Director, to the open market.

Stakeholder Impact

• Shareholders: A reduction in direct insider ownership, though mitigated by the 10b5-1 plan, could be perceived negatively by some investors.

Key Dates

Recommendation

The insider sale was conducted under a pre-established 10b5-1 trading plan, which suggests the transaction was not driven by new material non-public information. While it reduces insider ownership, it is a routine event for executives and does not inherently signal a change in the company's fundamental prospects. Therefore, a 'hold' recommendation is appropriate, pending further company-specific or market-wide developments.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, insider trading, Form 4, stock sale, 10b5-1 plan, common stock, officer, director